ArticleOncotarget2018
Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Early Prediction of the Breast Cancer Response to Neoadjuvant Chemotherapy Based on Intratumoral Interstitial Fluid Pressure using 3-D Subharmonic-Aided Pressure Estimation.Ultrasound in medicine & biology · 2026Article
- Recent advances in interstitial fluid dynamics for diagnostic, targeted drug delivery and precision medicine applications.Drug delivery and translational research · 2026Review
- Sphingolipid homeostasis and dysregulation in liver function and disease.Life metabolism · 2026Review
- Diffuse Midline Gliomas: Clinical, Diagnostic, and Therapeutic Perspectives.Biomedicines · 2026Review
- Brachytherapy-based multimodality cancer treatment: a concept and design perspective on devices to address the challenges of localized radiation therapy.Frontiers in oncology · 2026Article
- An Enhanced Scrutiny of Mechanistic and Translational Approaches to Extinguish Cancer Hypoxia.Pharmaceutical nanotechnology · 2026Review
- Evaluation of Bai-Zhu (BioMedicine · 2026Article
- Article
- Leveraging Immunological Properties of Nucleic Acid Nanoparticles to Improve Cancer Therapy.RNA nanomed · 2025Article
- A methotrexate labelled dual metal oxide nanocomposite for long-lasting anti-cancer theranostics.Materials today. Bio · 2025Article
- Theoretical Modeling of the Interactions of CoFeCurrent medicinal chemistry · 2025Article
- Distinct roles of small extracellular vesicles from resident and infiltrating macrophages on glioma growth and mobility.Journal of Cancer · 2025Article
- Innovative Approaches to Brain Cancer: The Use of Magnetic Resonance-guided Focused Ultrasound in Glioma Therapy.Cancers · 2024Review
- Biophysical and biochemical aspects of immune cell-tumor microenvironment interactions.APL bioengineering · 2024Review
- Advances in cancer mechanobiology: Metastasis, mechanics, and materials.APL bioengineering · 2024Review
- Improving targeted small molecule drugs to overcome chemotherapy resistance.Cancer reports (Hoboken, N.J.) · 2024Review
- On the role of myosin-induced actin depolymerization during cell migration.Molecular biology of the cell · 2023Article
- Review
- Article
- The RAGE/multiligand axis: a new actor in tumor biology.Bioscience reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Although a number of new systemic therapeutic options in patients with advanced solid cancers have emerged due to the improved knowledge of molecular dysregulation in cancers, the durable, long-term, objective responses infrequently occur. This editorial article highlights the major limitation of current systemic therapy due to an inefficient drug delivery. While several mechanisms contributing to cancer drug resistance have been described, the common key barrier among solid cancers is the unique tumor microenvironment that causes the high interstitial fluid pressure (IFP). We discussed the mechanism causing an elevated IFP and how it interferes with drug delivery. To target the high IFP, we demonstrated the novel approach using gold nanoparticle carrying recombinant human tumor necrosis factor (TNF), a vascular disrupting agent, that preferentially and specifically targets tumors while the systemic toxicity is markedly reduced. The addition of cytotoxic agent by either directly conjugating to the gold nanoparticle or by systemic administration following gold nanoparticle carrying TNF resulted in significantly reduced tumor burden and increased survival in multiple mouse models with primary and metastatic endocrine cancer and pancreatic ductal carcinoma. A clinical trial in patients with advanced solid cancers is warranted based on the promising results in preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.